Ocular Therapeutix commences dosing patients in OTX-DED Phase 2 trial

Ocular Therapeutix, one of the leading biopharmaceutical companies focused on development and commercialization of innovative therapies for conditions and diseases of the eye, has reportedly announced dosing the first candidate in its Phase 2 trial of OTX-DED for symptoms and signs of dry eye disease.

The Phase 2 clinical trial is expected to evaluate two distinguished-strength formulations of OTX-DED in over 150 patients suffering from dry eye disease. As per credible reports, the trial has been designed to study the efficiency and safety of two variations of OTX-DED for the short-term treatment of symptoms and signs of dry eye disease by analyzing corneal fluorescein staining eye dryness systems via making use of VAS and other subordinate endpoints.

Speaking on the latest accomplishment, President, Ophthalmology and CMO- Michael Goldstein, MD, MBA cited that Ocular Therapeutix is elated to have begun enrolling in and dosing patients in the Phase 2 clinical trial of OTX-DED.

He mentioned that OTX-DED stands to be new, investigations, preservative-free, and physician-administered intracanalicular insert developed to deliver either 0.2 or 0.3 milligram doses of dexamethasone that boasts of the potential to provide efficient treatment for dry eye issues.

He added that along with their OTX-CSI, the company boasts of two novel dry eye product candidates in Phase 2 development, one to acutely and other to chronically treat dry eye disease and problems, thereby efficiently spanning a broad gamut of about USD 5bn global dry eye disease industry.

it would be essential to mention that topical steroids are being generally used for the short-term treatment of dry eye problems. However, claims have been made that these products contain preservatives that can lead to ocular surface toxicities like stinging and itching, and when used more chronically, it can lead to other adverse effects like cataracts or elevated intraocular pressure. This has thus generated the demand for OTX-DED for several dry eye disease treatment.

Source Credit: https://www.businesswire.com/news/home/20210301005290/en/Ocular-Therapeutix%E2%84%A2-Announces-First-Patient-Dosed-in-Phase-2-Clinical-Trial-of-OTX-DED-for-the-Short-Term-Treatment-of-the-Signs-and-Symptoms-of-Dry-Eye-Disease